PET scintigraphy of etoposide-induced pulmonary toxicity.
A patient with chronic myelomonocytic leukemia developed drug-induced pulmonary toxicity after using low dose oral etoposide. Because etoposide-induced pulmonary toxicity is an uncommon but serious adverse event, clinicians must be vigilant about the possibility of it, so that the optimal treatment can start as soon as possible. This report demonstrates that PET scintigraphy might be a helpful tool in the early diagnosis of drug-induced pulmonary toxicity.
Post
Martijn C
MC
Department of Internal Medicine, St. Antonius Hospital, Nieuwegein, The Netherlands.
Grutters
Jan C
JC
Verzijlbergen
J Fred
JF
Biesma
Douwe H
DH
D000284:Administration, Oral; D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects*; D019788:Fluorodeoxyglucose F18; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy; D008171:Lung Diseases / Q000139:chemically induced* / Q000000981:diagnostic imaging*; D008297:Male; D049268:Positron-Emission Tomography / Q000379:methods*; D019275:Radiopharmaceuticals; D035583:Rare Diseases / Q000139:chemically induced / Q000000981:diagnostic imaging / Q000517:prevention & control
D000972:Antineoplastic Agents, Phytogenic; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18; D005047:Etoposide